155 related articles for article (PubMed ID: 33665229)
1. Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel.
Elango R; Vishnubalaji R; Shaath H; Alajez NM
Mol Ther Methods Clin Dev; 2021 Mar; 20():601-614. PubMed ID: 33665229
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of the TPX2/TTK network in colorectal cancer.
Shaath H; Vishnubalaji R; Elango R; Velayutham D; Jithesh PV; Alajez NM
Cell Commun Signal; 2023 Sep; 21(1):265. PubMed ID: 37770979
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq.
Vishnubalaji R; Alajez NM
Mol Ther Oncolytics; 2021 Dec; 23():151-162. PubMed ID: 34703883
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-Based Classification of Triple Negative Breast Cancer Revealed Inherent Tumor Heterogeneity and Vulnerabilities.
Vishnubalaji R; Elango R; Alajez NM
Noncoding RNA; 2022 Jun; 8(4):. PubMed ID: 35893227
[TBL] [Abstract][Full Text] [Related]
5. Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy.
Shaath H; Vishnubalaji R; Elango R; Khattak S; Alajez NM
Cell Death Discov; 2021 Jan; 7(1):23. PubMed ID: 33495450
[TBL] [Abstract][Full Text] [Related]
6. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
7. LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.
Maire V; Mahmood F; Rigaill G; Ye M; Brisson A; Némati F; Gentien D; Tucker GC; Roman-Roman S; Dubois T
Cancer Med; 2019 Jan; 8(1):325-336. PubMed ID: 30575334
[TBL] [Abstract][Full Text] [Related]
8. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G
Front Oncol; 2020; 10():1787. PubMed ID: 33042828
[No Abstract] [Full Text] [Related]
10. TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer.
Jiang Y; Liu Y; Tan X; Yu S; Luo J
Clin Breast Cancer; 2019 Dec; 19(6):450-455. PubMed ID: 31494045
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition.
Elango R; Vishnubalaji R; Shaath H; Alajez NM
Cancer Cell Int; 2021 Sep; 21(1):515. PubMed ID: 34565361
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping.
Yu X; Liu Y; Chen M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681552
[TBL] [Abstract][Full Text] [Related]
13. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
14. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.
Jiang YZ; Liu YR; Xu XE; Jin X; Hu X; Yu KD; Shao ZM
Cancer Res; 2016 Apr; 76(8):2105-14. PubMed ID: 26921339
[TBL] [Abstract][Full Text] [Related]
17. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
[No Abstract] [Full Text] [Related]
19. TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer.
King JL; Zhang B; Li Y; Li KP; Ni JJ; Saavedra HI; Dong JT
Oncogenesis; 2018 Sep; 7(9):69. PubMed ID: 30206215
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
